Re: [LymphomaVaccine] Ofatumumab in refractory CLL

[Guest guest]

Hi Jama,

The bottom line here, as I see it anyway, is a next generation rituxan-like

antibody with low toxicity was active and achieved responses in this very

difficult context: The overall response rate (ORR) to salvage therapy (of

any type) for such patients is approximately 20%

Fr Ofatumumab: te overall response rate was 51% in this study.

Also rituxan monotherapy is not often very effective in CLL even in more

favorable circumstances. So this bodes well for Ofatumumab approval I hope,

and it could lead to much better outcomes in CLL when Ofatumumbab is

combined with chemo and used earlier.

Karl

>

>

>

http://ash.confex.com/ash/2008/webprogram/Paper5918.html<http://ash.confex.com/a\

sh/2008/webprogram/Paper5918.html>

>

> n = 138 treated patients (Double refractory, n=59; Bulky fludarabine

> refractory, n=79